Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Springworks Therapeutics Inc (NQ: SWTX )

30.81 +0.74 (+2.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 502,885
Open 29.94
Bid (Size) 20.00 (1)
Ask (Size) 43.96 (10)
Prev. Close 30.07
Today's Range 29.94 - 31.27
52wk Range 13.60 - 65.92
Shares Outstanding 49,127,913
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via Globe NewsWire
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+17.28%
+17.28%
1 Month
+32.74%
+32.74%
3 Month
+21.49%
+21.49%
6 Month
+3.11%
+3.11%
1 Year
-40.73%
-40.73%

More News

Read More
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via Globe NewsWire
4 Analysts Have This to Say About SpringWorks Therapeutics
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging
Via Benzinga
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via Globe NewsWire
SpringWorks Therapeutics: Q3 Earnings Insights
Via Benzinga
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via Globe NewsWire
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
From SpringWorks Therapeutics, Inc.
Via Globe NewsWire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Via FinancialNewsMedia
Exposures COVID-19
NIO, Lucid Group And Other Big Gainers From Monday
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
SpringWorks Therapeutics: Q2 Earnings Insights
Via Benzinga
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Via Benzinga
70 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.